Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
1. To evaluate the safety, and efficacy of Lisdexamfetamine dimesylate in the treatment of
outpatients with DSM-IV ADHD with anxiety and depressive disorder comorbidity, as well
as to evaluate the effects on quality of life .
2. To evaluate the efficacy of Lisdexamfetamine dimesylate in the treatment of anxiety and
depressive disorders which commonly occur with ADHD.
3. To examine the potential relationship between telomere length and Adult ADHD with
comorbidity and the potential effect of treatment response.
4. To examine the potential associations with specific genes and Adult ADHD.
Phase:
Phase 4
Details
Lead Sponsor:
Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada